Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | CALML3 | P27482 | 1/20 | 0.61 |
| ▸ | SDHA | P31040 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295266 | 1.00 | MAOB (0.65) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL17066774 | 1.00 | MAOB (0.65) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL28431145 | 0.92 | MAOB (0.55) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL1955021 | 0.92 | MAOB (0.55) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL4167187 | 0.90 | MAOB (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2994083 | 0.87 | F10 (0.53) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL16701317 | 0.85 | CALML3 (0.49) | MAOBMAOACALML3 | |
| SCHEMBL16701320 | 0.85 | CALML3 (0.49) | MAOBMAOACALML3 | |
| SCHEMBL27552942 | 0.84 | RPS6KA3 (0.47) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL21360284 | 0.84 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | claimed |
| EP-1768967-B1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2009-04-22 | — | — | EP | claimed |
| US-7429661-B2 | Intermediates for linezolid and related compounds | SYMED LABS LIMITED (IN) | 2008-09-30 | — | — | US | claimed |
| US-7307163-B2 | Process for the preparation of linezolid and related compounds | SYMED LABS LIMITED (IN) | 2007-12-11 | — | — | US | claimed |
| EP-1737850-B1 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2007-10-03 | — | — | EP | claimed |
| EP-1768967-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | Symed Labs Limited (IN) | 2007-04-04 | — | — | EP | claimed |
| US-20070032472-A1 | Novel process for the preparation of linezolid and related compounds | SYMED LABS LIMITED (IN) | 2007-02-08 | — | — | US | claimed |
| EP-1737850-A2 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | Symed Labs Limited (IN) | 2007-01-03 | — | — | EP | claimed |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HETERO USA, INC. (US) | 2006-11-02 | — | — | US | claimed |
| WO-2006008754-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2006-01-26 | — | — | WO | claimed |
| WO-2005099353-A2 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2005-10-27 | — | — | WO | claimed |
| US-RE47606-E1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2019-09-17 | — | — | US | disclosed |
| US-RE47606-E1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2019-09-17 | — | — | US | disclosed |
| US-RE47606-E1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2019-09-17 | — | — | US | disclosed |
| WO-2018055499-A1 | ONE POT SYNTHESIS FOR THE PREPARATION OF SUBSTITUTED PHTHALIMIDO OXAZOLIDINONE ANTIBACTERIALS AND OXAZOLIDINONE ANTIHAROMBOTICS COMPOUNDS BY USING RECYCLABLE HETEROGENEOUS CATALYST | PHALANX LABS PRIVATE LIMITED (IN) | 2018-03-29 | — | — | WO | disclosed |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HETERO USA, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2005099353-A3 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006008754-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005099353-A2 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005099353-A2 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032472-A1 | Novel process for the preparation of linezolid and related compounds | EED, EML4, KDM5D | MAOB 946/4885MAOA 999/4885LMNA 1218/4885 |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HPD, PTMS, HDAC5 | MAOB 1181/4885MAOA 1155/4885LMNA 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.